Pomlimaid^® (Capsules) Instructions for Use

Marketing Authorization Holder

Izvarino Pharma LLC (Russia)

Manufactured By

Nanopharma Development, LLC (Russia)

ATC Code

L04AX06 (Pomalidomide)

Active Substance

Pomalidomide (Rec.INN registered by WHO)

Dosage Forms

	Pomlimaid^®	Capsules 1 mg
		Capsules 2 mg
		Capsules 3 mg
		Capsules 4 mg

Dosage Form, Packaging, and Composition

Capsules

	1 caps.
Pomalidomide	1 mg

10 pcs. – blister packs – cardboard packs (10 pcs.) – Prescription only
10 pcs. – blister packs (10 pcs.) – cardboard packs (100 pcs.) – Prescription only
10 pcs. – blister packs (150 pcs.) – cardboard boxes (1500 pcs.) – In-Bulk
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – Prescription only
10 pcs. – blister packs (200 pcs.) – cardboard boxes (2000 pcs.) – In-Bulk
10 pcs. – blister packs (3 pcs.) – cardboard packs (30 pcs.) – Prescription only
10 pcs. – blister packs (300 pcs.) – cardboard boxes (3000 pcs.) – In-Bulk
10 pcs. – blister packs (4 pcs.) – cardboard packs (40 pcs.) – Prescription only
10 pcs. – blister packs (400 pcs.) – cardboard boxes (4000 pcs.) – In-Bulk
10 pcs. – blister packs (5 pcs.) – cardboard packs (50 pcs.) – Prescription only
10 pcs. – blister packs (500 pcs.) – cardboard boxes (5000 pcs.) – In-Bulk
10 pcs. – blister packs (6 pcs.) – cardboard packs (60 pcs.) – Prescription only
10 pcs. – blister packs (600 pcs.) – cardboard boxes (6000 pcs.) – In-Bulk
10 pcs. – blister packs (7 pcs.) – cardboard packs (70 pcs.) – Prescription only
10 pcs. – blister packs (8 pcs.) – cardboard packs (80 pcs.) – Prescription only
10 pcs. – blister packs (9 pcs.) – cardboard packs (90 pcs.) – Prescription only
14 pcs. – blister packs – cardboard packs (14 pcs.) – Prescription only
14 pcs. – blister packs (10 pcs.) – cardboard packs (140 pcs.) – Prescription only
14 pcs. – blister packs (150 pcs.) – cardboard boxes (2100 pcs.) – In-Bulk
14 pcs. – blister packs (2 pcs.) – cardboard packs (28 pcs.) – Prescription only
14 pcs. – blister packs (200 pcs.) – cardboard boxes (2800 pcs.) – In-Bulk
14 pcs. – blister packs (3 pcs.) – cardboard packs (42 pcs.) – Prescription only
14 pcs. – blister packs (300 pcs.) – cardboard boxes (4200 pcs.) – In-Bulk
14 pcs. – blister packs (4 pcs.) – cardboard packs (56 pcs.) – Prescription only
14 pcs. – blister packs (400 pcs.) – cardboard boxes (5600 pcs.) – In-Bulk
14 pcs. – blister packs (5 pcs.) – cardboard packs (70 pcs.) – Prescription only
14 pcs. – blister packs (500 pcs.) – cardboard boxes (7000 pcs.) – In-Bulk
14 pcs. – blister packs (6 pcs.) – cardboard packs (84 pcs.) – Prescription only
14 pcs. – blister packs (600 pcs.) – cardboard boxes (8400 pcs.) – In-Bulk
14 pcs. – blister packs (7 pcs.) – cardboard packs (98 pcs.) – Prescription only
14 pcs. – blister packs (8 pcs.) – cardboard packs (112 pcs.) – Prescription only
14 pcs. – blister packs (9 pcs.) – cardboard packs (126 pcs.) – Prescription only
4 pcs. – blister packs – cardboard packs (4 pcs.) – Prescription only
4 pcs. – blister packs (10 pcs.) – cardboard packs (40 pcs.) – Prescription only
4 pcs. – blister packs (150 pcs.) – cardboard boxes (600 pcs.) – In-Bulk
4 pcs. – blister packs (2 pcs.) – cardboard packs (8 pcs.) – Prescription only
4 pcs. – blister packs (200 pcs.) – cardboard boxes (800 pcs.) – In-Bulk
4 pcs. – blister packs (3 pcs.) – cardboard packs (12 pcs.) – Prescription only
4 pcs. – blister packs (300 pcs.) – cardboard boxes (1200 pcs.) – In-Bulk
4 pcs. – blister packs (4 pcs.) – cardboard packs (16 pcs.) – Prescription only
4 pcs. – blister packs (400 pcs.) – cardboard boxes (1600 pcs.) – In-Bulk
4 pcs. – blister packs (5 pcs.) – cardboard packs (20 pcs.) – Prescription only
4 pcs. – blister packs (500 pcs.) – cardboard boxes (2000 pcs.) – In-Bulk
4 pcs. – blister packs (6 pcs.) – cardboard packs (24 pcs.) – Prescription only
4 pcs. – blister packs (600 pcs.) – cardboard boxes (2400 pcs.) – In-Bulk
4 pcs. – blister packs (7 pcs.) – cardboard packs (28 pcs.) – Prescription only
4 pcs. – blister packs (8 pcs.) – cardboard packs (32 pcs.) – Prescription only
4 pcs. – blister packs (9 pcs.) – cardboard packs (36 pcs.) – Prescription only
5 pcs. – blister packs – cardboard packs (5 pcs.) – Prescription only
5 pcs. – blister packs (10 pcs.) – cardboard packs (50 pcs.) – Prescription only
5 pcs. – blister packs (150 pcs.) – cardboard boxes (750 pcs.) – In-Bulk
5 pcs. – blister packs (2 pcs.) – cardboard packs (10 pcs.) – Prescription only
5 pcs. – blister packs (200 pcs.) – cardboard boxes (1000 pcs.) – In-Bulk
5 pcs. – blister packs (3 pcs.) – cardboard packs (15 pcs.) – Prescription only
5 pcs. – blister packs (300 pcs.) – cardboard boxes (1500 pcs.) – In-Bulk
5 pcs. – blister packs (4 pcs.) – cardboard packs (20 pcs.) – Prescription only
5 pcs. – blister packs (400 pcs.) – cardboard boxes (2000 pcs.) – In-Bulk
5 pcs. – blister packs (5 pcs.) – cardboard packs (25 pcs.) – Prescription only
5 pcs. – blister packs (500 pcs.) – cardboard boxes (2500 pcs.) – In-Bulk
5 pcs. – blister packs (6 pcs.) – cardboard packs (30 pcs.) – Prescription only
5 pcs. – blister packs (600 pcs.) – cardboard boxes (3000 pcs.) – In-Bulk
5 pcs. – blister packs (7 pcs.) – cardboard packs (35 pcs.) – Prescription only
5 pcs. – blister packs (8 pcs.) – cardboard packs (40 pcs.) – Prescription only
5 pcs. – blister packs (9 pcs.) – cardboard packs (45 pcs.) – Prescription only
7 pcs. – blister packs – cardboard packs (7 pcs.) – Prescription only
7 pcs. – blister packs (10 pcs.) – cardboard packs (70 pcs.) – Prescription only
7 pcs. – blister packs (150 pcs.) – cardboard boxes (1050 pcs.) – In-Bulk
7 pcs. – blister packs (2 pcs.) – cardboard packs (14 pcs.) – Prescription only
7 pcs. – blister packs (200 pcs.) – cardboard boxes (1400 pcs.) – In-Bulk
7 pcs. – blister packs (3 pcs.) – cardboard packs (21 pcs.) – Prescription only
7 pcs. – blister packs (300 pcs.) – cardboard boxes (2100 pcs.) – In-Bulk
7 pcs. – blister packs (4 pcs.) – cardboard packs (28 pcs.) – Prescription only
7 pcs. – blister packs (400 pcs.) – cardboard boxes (2800 pcs.) – In-Bulk
7 pcs. – blister packs (5 pcs.) – cardboard packs (35 pcs.) – Prescription only
7 pcs. – blister packs (500 pcs.) – cardboard boxes (3500 pcs.) – In-Bulk
7 pcs. – blister packs (6 pcs.) – cardboard packs (42 pcs.) – Prescription only
7 pcs. – blister packs (600 pcs.) – cardboard boxes (4200 pcs.) – In-Bulk
7 pcs. – blister packs (7 pcs.) – cardboard packs (49 pcs.) – Prescription only
7 pcs. – blister packs (8 pcs.) – cardboard packs (56 pcs.) – Prescription only
7 pcs. – blister packs (9 pcs.) – cardboard packs (63 pcs.) – Prescription only

Capsules

	1 caps.
Pomalidomide	2 mg

Capsules

	1 caps.
Pomalidomide	3 mg

Capsules

	1 caps.
Pomalidomide	4 mg

10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (150 pcs.) – cardboard boxes (1500 pcs.) – In-Bulk
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (200 pcs.) – cardboard boxes (2000 pcs.) – In-Bulk
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (300 pcs.) – cardboard boxes (3000 pcs.) – In-Bulk
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (400 pcs.) – cardboard boxes (4000 pcs.) – In-Bulk
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (500 pcs.) – cardboard boxes (5000 pcs.) – In-Bulk
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (600 pcs.) – cardboard boxes (6000 pcs.) – In-Bulk
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (150 pcs.) – cardboard boxes (2100 pcs.) – In-Bulk
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (200 pcs.) – cardboard boxes (2800 pcs.) – In-Bulk
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (300 pcs.) – cardboard boxes (4200 pcs.) – In-Bulk
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (400 pcs.) – cardboard boxes (5600 pcs.) – In-Bulk
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (500 pcs.) – cardboard boxes (7000 pcs.) – In-Bulk
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (600 pcs.) – cardboard boxes (8400 pcs.) – In-Bulk
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
4 pcs. – contour cell packs – cardboard packs (4 pcs.) – By prescription
4 pcs. – contour cell packs (10 pcs.) – cardboard packs (40 pcs.) – By prescription
4 pcs. – contour cell packs (150 pcs.) – cardboard boxes (600 pcs.) – In-Bulk
4 pcs. – contour cell packs (2 pcs.) – cardboard packs (8 pcs.) – By prescription
4 pcs. – contour cell packs (200 pcs.) – cardboard boxes (800 pcs.) – In-Bulk
4 pcs. – contour cell packs (3 pcs.) – cardboard packs (12 pcs.) – By prescription
4 pcs. – contour cell packs (300 pcs.) – cardboard boxes (1200 pcs.) – In-Bulk
4 pcs. – contour cell packs (4 pcs.) – cardboard packs (16 pcs.) – By prescription
4 pcs. – contour cell packs (400 pcs.) – cardboard boxes (1600 pcs.) – In-Bulk
4 pcs. – contour cell packs (5 pcs.) – cardboard packs (20 pcs.) – By prescription
4 pcs. – contour cell packs (500 pcs.) – cardboard boxes (2000 pcs.) – In-Bulk
4 pcs. – contour cell packs (6 pcs.) – cardboard packs (24 pcs.) – By prescription
4 pcs. – contour cell packs (600 pcs.) – cardboard boxes (2400 pcs.) – In-Bulk
4 pcs. – contour cell packs (7 pcs.) – cardboard packs (28 pcs.) – By prescription
4 pcs. – contour cell packs (8 pcs.) – cardboard packs (32 pcs.) – By prescription
4 pcs. – contour cell packs (9 pcs.) – cardboard packs (36 pcs.) – By prescription
5 pcs. – contour cell packs – cardboard packs (5 pcs.) – By prescription
5 pcs. – contour cell packs (10 pcs.) – cardboard packs (50 pcs.) – By prescription
5 pcs. – contour cell packs (150 pcs.) – cardboard boxes (750 pcs.) – In-Bulk
5 pcs. – contour cell packs (2 pcs.) – cardboard packs (10 pcs.) – By prescription
5 pcs. – contour cell packs (200 pcs.) – cardboard boxes (1000 pcs.) – In-Bulk
5 pcs. – contour cell packs (3 pcs.) – cardboard packs (15 pcs.) – By prescription
5 pcs. – contour cell packs (300 pcs.) – cardboard boxes (1500 pcs.) – In-Bulk
5 pcs. – contour cell packs (4 pcs.) – cardboard packs (20 pcs.) – By prescription
5 pcs. – contour cell packs (400 pcs.) – cardboard boxes (2000 pcs.) – In-Bulk
5 pcs. – contour cell packs (5 pcs.) – cardboard packs (25 pcs.) – By prescription
5 pcs. – contour cell packs (500 pcs.) – cardboard boxes (2500 pcs.) – In-Bulk
5 pcs. – contour cell packs (6 pcs.) – cardboard packs (30 pcs.) – By prescription
5 pcs. – contour cell packs (600 pcs.) – cardboard boxes (3000 pcs.) – In-Bulk
5 pcs. – contour cell packs (7 pcs.) – cardboard packs (35 pcs.) – By prescription
5 pcs. – contour cell packs (8 pcs.) – cardboard packs (40 pcs.) – By prescription
5 pcs. – contour cell packs (9 pcs.) – cardboard packs (45 pcs.) – By prescription
7 pcs. – contour cell packs – cardboard packs (7 pcs.) – By prescription
7 pcs. – contour cell packs (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – contour cell packs (150 pcs.) – cardboard boxes (1050 pcs.) – In-Bulk
7 pcs. – contour cell packs (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – contour cell packs (200 pcs.) – cardboard boxes (1400 pcs.) – In-Bulk
7 pcs. – contour cell packs (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – contour cell packs (300 pcs.) – cardboard boxes (2100 pcs.) – In-Bulk
7 pcs. – contour cell packs (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – contour cell packs (400 pcs.) – cardboard boxes (2800 pcs.) – In-Bulk
7 pcs. – contour cell packs (5 pcs.) – cardboard packs (35 pcs.) – By prescription
7 pcs. – contour cell packs (500 pcs.) – cardboard boxes (3500 pcs.) – In-Bulk
7 pcs. – contour cell packs (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – contour cell packs (600 pcs.) – cardboard boxes (4200 pcs.) – In-Bulk
7 pcs. – contour cell packs (7 pcs.) – cardboard packs (49 pcs.) – By prescription
7 pcs. – contour cell packs (8 pcs.) – cardboard packs (56 pcs.) – By prescription
7 pcs. – contour cell packs (9 pcs.) – cardboard packs (63 pcs.) – By prescription

Clinical-Pharmacological Group

Immunomodulator with antitumor activity

Pharmacotherapeutic Group

Immunosuppressants; other immunosuppressants

Pharmacological Action

Pomalidomide has direct antimyeloma tumoricidal activity, demonstrates immunomodulatory effects, and inhibits stromal cells that support myeloma tumor cell growth.

It selectively inhibits the proliferation and induces apoptosis of hematopoietic tumor cells.

Furthermore, Pomalidomide inhibits the proliferation of multiple myeloma cell lines resistant to lenalidomide and exhibits synergy with dexamethasone in inducing apoptosis of both lenalidomide-sensitive and resistant tumor cell lines.

Pomalidomide enhances cellular immunity involving T-cells and natural killer cells and inhibits the production of pro-inflammatory cytokines (e.g., TNFα and interleukin-6) by monocytes.

Pomalidomide also inhibits angiogenesis by blocking endothelial cell migration and adhesion.

Pharmacokinetics

After a single oral dose, the absorption of pomalidomide is at least 73%, and its C_max in plasma is reached within 2 hours.

The systemic exposure of pomalidomide (by AUC) increases nearly linearly and proportionally to the dose.

With multiple dosing, the extent of pomalidomide accumulation is 27-31% based on AUC.

When taken with a high-calorie, high-fat meal, the absorption rate of pomalidomide is slowed, the mean C_max is reduced by approximately 27%, but the overall absorption is practically unchanged, the mean AUC decreases by 8%, so Pomalidomide can be taken regardless of food intake.

The mean apparent V_d of pomalidomide at steady state ranges from 62 to 138 L.

After administration for 3 days at 2 mg/day, Pomalidomide was detected in the semen of healthy volunteers at a concentration of approximately 67% of the plasma level, which is reached at 4 hours (approximate T_max) after drug intake.

In vitro, the binding of pomalidomide enantiomers to human plasma proteins ranges from 12% to 44% and is concentration-independent.

In healthy volunteers after a single oral dose of [¹⁴C]-pomalidomide (2 mg), the main radioactive component in the blood was Pomalidomide (approximately 70% of plasma radioactivity).

The amount of metabolites did not exceed 10% relative to the parent compound or total plasma radioactivity.

Hydroxylation followed by glucuronidation or hydrolysis is the main metabolic pathway for excreted radioactivity.

In vitro, CYP1A2 and CYP3A4 isoenzymes were the primary enzymes involved in the hydroxylation of pomalidomide.

CYP2C19 and CYP2D6 isoenzymes played a lesser role.

Pomalidomide is also a substrate of Pgp in vitro.

The mean T_1/2 of pomalidomide from plasma is 9.5 hours in healthy volunteers and 7.5 hours in patients with multiple myeloma.

The mean total clearance of the drug is approximately 7-10 L/h.

In healthy volunteers after a single oral dose of [¹⁴C]-pomalidomide (2 mg), approximately 73% and 15% of the radioactive dose was excreted renally and via the intestine, respectively, with about 2% and 8% of the carbon-labeled pomalidomide dose excreted renally and via the intestine unchanged.

Pomalidomide undergoes significant biotransformation, and the resulting metabolites are excreted primarily by the kidneys.

The three main metabolites, formed by hydrolysis or hydroxylation followed by glucuronidation, account for 23%, 17%, and 12% of the total metabolite content in urine, respectively.

The amount of metabolites formed via cytochrome P450 was approximately 43% of the total radioactivity, and non-CYP-dependent hydrolytic metabolites accounted for 25%.

Unchanged pomalidomide accounts for 10% of the excretion (2% renally and 8% via the intestine).

Indications

In combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have demonstrated disease progression on the last therapy.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
C90.0	Multiple myeloma

ICD-11 code	Indication
2A83.1	Plasma cell myeloma

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take capsules orally with water. Swallow capsules whole; do not chew, crush, or open.

The recommended starting dose is 4 mg once daily. Administer doses on Days 1 to 21 of repeated 28-day cycles.

Take doses at approximately the same time each day. Administration is permitted with or without food.

For dose adjustments due to adverse reactions, follow these steps. For Grade 3 or 4 neutropenia: interrupt treatment until ANC returns to at least 0.5 x 10⁹/L, then resume at 3 mg daily. For subsequent occurrences, interrupt and resume at 2 mg daily.

For Grade 3 or 4 thrombocytopenia: interrupt treatment until platelet count returns to at least 50 x 10⁹/L, then resume at 3 mg daily. For subsequent occurrences, interrupt and resume at 2 mg daily.

For other Grade 3 or 4 toxicities (excluding rash): interrupt treatment until resolved to Grade 2 or lower, then resume at the next lower dose.

For Grade 2 or 3 rash, interrupt treatment. Resume at the same dose only after rash resolves to Grade 1 or lower. For Grade 4 rash, discontinue treatment permanently.

Perform complete blood counts weekly for the first 8 weeks and monthly thereafter. Monitor patients for hematological toxicity, especially neutropenia and thrombocytopenia.

Continue treatment until disease progression or unacceptable toxicity occurs. All dose modifications are based on physician assessment of clinical and laboratory parameters.

Adverse Reactions

Infections and infestations very common – bacterial, viral, and fungal infections, including opportunistic infections; common – neutropenic sepsis, respiratory tract infections, upper respiratory tract infections, herpes zoster; frequency unknown – reactivation of hepatitis B virus.

Benign, malignant and unspecified neoplasms (including cysts and polyps) uncommon – basal cell carcinoma of the skin, squamous cell carcinoma of the skin.

Blood and lymphatic system disorders very common – neutropenia, thrombocytopenia, leukopenia, anemia; common – febrile neutropenia, pancytopenia.

Immune system disorders common – angioedema, urticaria.

Metabolism and nutrition disorders common – hyperkalemia, hyponatremia, hyperuricemia; uncommon – tumor lysis syndrome.

Psychiatric disorders common – confusion.

Nervous system disorders common – lethargy, peripheral sensory neuropathy, dizziness, tremor, intracranial hemorrhage; uncommon – stroke.

Ear and labyrinth disorders common – vertigo.

Cardiac disorders common – heart failure, atrial fibrillation, myocardial infarction, deep vein thrombosis.

Vascular disorders common – pulmonary embolism.

Respiratory, thoracic and mediastinal disorders very common – dyspnea, cough, pneumonia; common – pulmonary embolism, epistaxis, nasopharyngitis, interstitial lung disease, bronchopneumonia, bronchitis.

Gastrointestinal disorders very common – decreased appetite, diarrhea, nausea, constipation; common – vomiting, gastrointestinal hemorrhage, increased ALT; uncommon – hyperbilirubinemia, hepatitis.

Skin and subcutaneous tissue disorders common – rash, pruritus; frequency unknown – DRESS syndrome, toxic epidermal necrolysis, Stevens-Johnson syndrome.

Musculoskeletal and connective tissue disorders very common – bone pain, muscle spasms.

Renal and urinary disorders common – renal failure, urinary retention.

General disorders and administration site conditions very common – fatigue, pyrexia, peripheral edema; common – pelvic pain, increased plasma uric acid concentration.

Contraindications

Hypersensitivity to pomalidomide; pregnancy, breastfeeding; women of childbearing potential, except when all necessary conditions of the Pregnancy Prevention Program are met; men who are unable or unwilling to adhere to the required contraceptive measures; age under 18 years.

Use with caution in patients with renal and/or hepatic impairment, deep vein thrombosis (including history), advanced stage disease and/or high tumor burden due to the potential risk of tumor lysis syndrome, neuropathy (including history), presence of risk factors for thromboembolism (heart or lung disease, hypertension, elevated blood cholesterol, smokers), when used concomitantly with drugs that increase the risk of thrombosis (including drugs with erythropoietic activity, hormone replacement therapy).

Use in Pregnancy and Lactation

Contraindicated during pregnancy.

Women of childbearing potential must use one highly effective method of contraception for 4 weeks before starting treatment, during treatment, and for 4 weeks after completion of pomalidomide treatment, even in case of treatment interruption.

The exception is patients who have been continuously and completely abstinent from sexual intercourse for a long time, as confirmed monthly.

If an effective contraceptive method has not been selected for the patient, she should be referred to a gynecologist for selection and initiation of a contraceptive method.

In accordance with accepted practice, pregnancy tests with a minimum sensitivity of 25 mIU/ml must be performed under physician supervision for all women of childbearing potential, including those who are completely and continuously abstinent from sexual intercourse.

Given the potential adverse effects of pomalidomide on newborns, either breastfeeding or drug administration should be discontinued, taking into account the importance of breastfeeding and treatment for the mother.

Use in Hepatic Impairment

No initial dose adjustment of pomalidomide is required in patients with hepatic impairment.

Use in Renal Impairment

No dose adjustment of pomalidomide is required in patients with renal impairment.

Pediatric Use

Contraindicated in patients under 18 years of age.

Geriatric Use

No dose adjustment is required in elderly patients.

Special Precautions

Treatment with pomalidomide should be initiated and conducted under the supervision of an experienced hematologist or oncologist.

Strict adherence to all requirements of the Pregnancy Prevention Program must apply to all patients unless the absence of childbearing potential is reliably proven.

The use of combined oral contraceptives is not recommended in patients with multiple myeloma due to the increased risk of thromboembolic complications during treatment with pomalidomide and dexamethasone.

The increased risk of thromboembolism persists for 4-6 weeks after discontinuation of combined contraceptive use.

The effectiveness of hormonal contraceptives may be reduced with concomitant administration of dexamethasone.

The use of subcutaneous hormonal implants or intrauterine systems releasing levonorgestrel is associated with an increased risk of infectious complications at the time of insertion and with irregular vaginal bleeding.

Patients with neutropenia using these contraceptive methods should be prophylactically prescribed antibiotics.

The use of copper-releasing intrauterine systems is generally not recommended due to the high risk of infectious complications at implantation and increased blood loss during menstruation, which may exacerbate neutropenia or thrombocytopenia.

Pomalidomide may be present in the patient’s semen during treatment.

As a precaution and taking into account special patient groups with potentially prolonged elimination time, e.g., those with hepatic impairment, all men taking Pomalidomide should consider the potential risk of teratogenic effects of pomalidomide during sexual contact with a pregnant woman or a woman of childbearing potential.

Condoms must be used during sexual contact with a pregnant woman or a woman of childbearing potential not using reliable contraception, during treatment, during treatment interruption, and for 7 days after treatment suspension and/or completion.

This recommendation also applies to men after vasectomy, who should also use a condom during sexual contact with a pregnant woman or a woman of childbearing potential, as even in the absence of sperm, their semen may contain Pomalidomide.

If a partner becomes pregnant during his treatment with pomalidomide or within 7 days after discontinuation of pomalidomide therapy, the man should immediately inform his treating physician, and his partner is advised to consult a teratology specialist for examination and counseling.

Patients are not permitted to be donors of blood, semen, or sperm throughout the entire duration of treatment (including treatment interruptions) and for 7 days after completion of pomalidomide intake.

In patients with relapsed/refractory multiple myeloma, the most frequently reported Grade 3 or 4 adverse event is neutropenia; the next most frequent are anemia and thrombocytopenia. Patients should be monitored for hematological adverse reactions, especially neutropenia. Patients should be informed of the need to promptly report fever. Physicians should monitor patients for symptoms of increased bleeding, including epistaxis, especially during concomitant therapy with drugs that increase the risk of bleeding. A complete blood count should be performed before initiation of treatment, then weekly for the first 8 weeks of treatment, and subsequently once a month. Dose adjustment of pomalidomide, use of blood substitutes and/or growth factor preparations may be required.

Venous thromboembolic events (primarily deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and stroke) have occurred in patients treated with pomalidomide in combination with dexamethasone. Patients with risk factors for thromboembolism, including prior thrombosis, should be under careful observation. All possible measures should be taken to minimize risk factors (e.g., smoking, hypertension, hyperlipidemia). Patients and physicians should monitor for signs and symptoms of thromboembolism. Patients should be warned to seek medical attention if symptoms such as shortness of breath, chest pain, or swelling of the upper and lower extremities occur. If there are no contraindications, treatment with anticoagulants (such as acetylsalicylic acid, warfarin, heparin, or clopidogrel) is recommended, especially in patients with additional risk factors for thrombosis.

The use of erythropoietic agents is associated with a risk of thrombotic complications, including thromboembolism. Consequently, erythropoietic drugs, as well as other agents that may increase the risk of thromboembolism, should be used with caution.

Complications in the form of heart failure, including congestive heart failure and pulmonary edema, were noted mainly in patients with pre-existing heart failure or risk factors for heart disease. Caution should be exercised when considering treatment with pomalidomide in such patients, including regular check-ups to detect symptoms of heart failure.

The greatest risk of tumor lysis syndrome exists in patients with a high tumor burden at the start of treatment. Close monitoring of such patients with appropriate prophylactic measures is necessary.

The occurrence of primary malignancies at other sites, such as non-melanoma skin cancer, has been reported in patients receiving Pomalidomide. Patients should be thoroughly examined before and during treatment using standard cancer screening methods to detect primary tumors at other sites and, if necessary, appropriate treatment should be prescribed.

Angioedema and severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome, have been reported during the use of pomalidomide. Patients should be informed about the signs and symptoms of these reactions and warned to seek immediate medical attention if such symptoms appear. Pomalidomide treatment should be discontinued if exfoliative or bullous rash develops or if Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome is suspected. Treatment should not be resumed after resolution of the aforementioned reactions.

Patients with a history of serious allergic reactions to thalidomide or lenalidomide may have an increased risk of hypersensitivity reactions and should not receive Pomalidomide. Interruption or discontinuation of pomalidomide treatment should be considered in case of Grade 2-3 skin rash. If angioedema develops, Pomalidomide must be discontinued.

There have been reports of dizziness and confusion during pomalidomide administration. Patients should avoid situations where dizziness and confusion could be problematic and should not take other medications that may cause similar disturbances without prior medical consultation.

Interstitial lung disease and other similar phenomena, including cases of pneumonitis, have been observed during treatment with pomalidomide. Patients with acute symptoms or unexplained worsening of pulmonary symptoms should undergo a thorough examination to rule out interstitial lung disease. During this examination, pomalidomide treatment should be suspended, and if interstitial lung disease is confirmed, appropriate therapy should be initiated. Pomalidomide treatment may be resumed only after a careful benefit-risk assessment.

Marked increases in ALT activity and bilirubin concentration have been observed in patients taking Pomalidomide. Cases of hepatitis leading to discontinuation of pomalidomide treatment have also been reported. Regular monitoring of liver function is recommended during the first 6 months of pomalidomide therapy and thereafter as clinically indicated.

Rare cases of hepatitis B virus reactivation have been reported in patients previously infected with hepatitis B virus during treatment with pomalidomide in combination with dexamethasone. In several cases, hepatitis progressed to acute liver failure, resulting in discontinuation of Pomalidomide. Testing for the presence and activity of hepatitis B virus should be performed before starting treatment with pomalidomide. For patients with a positive test for hepatitis B virus, consultation with a physician experienced in the treatment of patients with viral hepatitis B is recommended. Caution should be exercised when using pomalidomide and dexamethasone concomitantly in patients with a history of viral hepatitis B. Such patients should be closely monitored throughout the course of therapy for timely detection of symptoms and signs of active disease caused by the hepatitis B virus.

Effect on Ability to Drive and Use Machines

Pomalidomide has minor to moderate influence on the ability to drive and use machines. Some side effects of pomalidomide, such as fatigue, lethargy, confusion, and dizziness, may adversely affect the ability to drive a car and perform potentially hazardous activities requiring increased concentration and speed of psychomotor reactions. If such adverse events occur, one should refrain from performing these activities.

Drug Interactions

Pomalidomide is partially metabolized by CYP1A2 and CYP3A4/5 isoenzymes and is a substrate for Pgp. If a strong inhibitor of the CYP1A2 isoenzyme (e.g., ciprofloxacin, enoxacin, or fluvoxamine) is used concomitantly with pomalidomide, the dose of pomalidomide should be reduced by 50%.

Monitoring of warfarin concentration is recommended during combination therapy.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer